Association of PIK3CA gene mutations with head and neck squamous cell carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) gene is crucial in cell signaling and frequently altered in human cancers.
• PIK3CA mutations are linked to aggressive cancer progression and aberrant cellular mechanisms.
• Understanding PIK3CA gene alterations in head and neck squamous cell carcinomas (HNSCC) is vital for targeted therapies.

Purpose of the Study:

• To investigate mutations within the helical (exon 9) and kinase (exon 20) domains of the PIK3CA gene in HNSCC patients.
• To correlate PIK3CA mutations with demographic and clinical parameters in HNSCC.
• To evaluate the potential of PIK3CA mutations as prognostic biomarkers and therapeutic targets in HNSCC.

Main Methods:

• Screening of PIK3CA gene mutations in 129 HNSCC patients and 150 healthy controls.
• Utilizing Polymerase Chain Reaction (PCR), Single-Strand Conformation Polymorphism (SSCP), and Sanger Sequencing for mutation detection.
• Analyzing mutations in the helical and kinase domains of PIK3CA.

Main Results:

• Approximately 60.46% of HNSCC patients and 26% of controls exhibited PIK3CA mutations (1634A>C [E545A] and 3075C>T [T1025T]).
• These specific PIK3CA mutations were more prevalent in oral cancers, advanced HNSCC stages, and individuals with combined tobacco and alcohol habits (p<0.05).
• A significant association was observed between PIK3CA mutation distribution and demographic/clinical factors in HNSCC.

Conclusions:

• PIK3CA mutations in HNSCC are associated with key demographic (tobacco, alcohol) and clinical (advanced stage, primary site) factors.
• Overactive PI3K signaling due to PIK3CA mutations may promote tumor cell proliferation by inhibiting apoptosis.
• Identified PIK3CA mutations represent potential prognostic biomarkers and novel therapeutic targets for HNSCC treatment.